Sanara MedTech achieved net revenue of $26.3 million in Q4 2024, representing a 49% increase compared to the prior year. Gross profit rose to $24.1 million with a strong margin of 91%. Despite these gains, the company recorded a net loss of $1.7 million, influenced by higher SG&A and R&D costs, as well as increased interest expenses.
Q4 2024 net revenue rose 49% year-over-year to $26.3 million.
Gross profit reached $24.1 million, with a 91% gross margin.
Net loss widened to $1.7 million, impacted by increased SG&A, R&D, and interest expenses.
Soft tissue repair products sales increased 56%, driving overall revenue growth.
Sanara MedTech plans to continue investing in its Tissue Health Plus platform in 2025, with a pilot program launch expected in Q2, while focusing on profitability improvements in the Sanara Surgical segment.
Visualization of income flow from segment revenue to net income
Analyze how earnings announcements historically affect stock price performance